ZMapp is granted fast track approval in America. LeafBio says the grant is an “important milestone” which brings them closer to eventually gaining approval. The drug has been administered under emergency use authorization to nine infected patients in Africa in addition to two infected missionaries in Europe during its first clinical trial. LeafBio CEO Whaley:
We are gratified to receive this designation for ZMapp. We are hopeful that this step will accelerate its access once safety and efficacy are demonstrated to satisfaction by FDA in ongoing clinical trials.